Related Experiment Videos
The EU's new paediatric medicines legislation: serving children's needs?
Govin Permanand1, Elias Mossialos, Martin McKee
1LSE Health and European Observatory on Health Systems and Policies, London School of Economics and Political Science, Houghton Street, London WC2A 2AE, UK. g.permanand@lse.ac.uk
Archives of Disease in Childhood
|August 24, 2007
Summary
New European Union legislation for pediatric medicines aims to improve children's access to drugs but has notable gaps. The law, compared to US regulations, falls short of expectations, presenting a missed opportunity for clear guidelines.
Area of Science:
- Pediatric medicine regulation
- European Union health policy
- Pharmaceutical legislation
Background:
- European Union (EU) legislation for pediatric medicines enacted January 26, 2007.
- Addresses unresolved issues concerning children's medicine needs in Europe.
- Aims to improve pediatric drug availability and research.
Purpose of the Study:
- Review the main proposals of the EU pediatric medicines legislation.
- Compare the EU legislation with equivalent regulations in the USA.
- Identify gaps and uncertainties within the new legislation.
Main Methods:
- Legislative review of the EU pediatric medicines regulation.
- Comparative analysis between EU and US pharmaceutical laws for children.
- Critical assessment of the legislation's proposals and objectives.
Main Results:
- The legislation presents several gaps and uncertainties.
- The intended aims of the legislation are not fully met.
- The EU's opportunity to surpass US regulations was not fully realized.
Conclusions:
- The EU pediatric medicines legislation, while well-intentioned, is disappointing.
- Further refinement is needed to address identified shortcomings.
- The legislation represents a missed opportunity for comprehensive pediatric drug policy.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...